Decoding biology demands a bold approach.
Biology is enormously complex and highly networked.
As a species, we so far only understand a tiny fraction of all there is to learn on the subject, despite millions of incredible scientists having dedicated their lives to uncovering its truths. Unraveling the complexity of biology is a path to better medicines.
The emergence of radical technological innovations has created the opportunity to envision new approaches to discovering therapeutics more efficiently and at scale. We are pioneering the integration of these technological innovations across biology, chemistry, automation, data science, and engineering to modernize drug discovery and development.
Eroom’s Law
Drug discovery is becoming slower and more expensive over time
The biopharmaceutical industry faces pressure amidst declining efficiency in drug discovery.
Moore’s Law
Meanwhile computing power is becoming faster and less expensive over time
The biopharmaceutical industry has historically lacked the tools to understand biology’s complexity.
The opportunity
Recursion is leveraging technology to industrialize drug discovery
Recursion was founded to take advantage of the discontinuity between these fields and harness the power of accelerating technological innovations to improve the efficiency of drug discovery and development.
Eroom’s Law
Drug discovery is becoming slower and more expensive over time
The biopharmaceutical industry faces pressure amidst declining efficiency in drug discovery.
Moore’s Law
Meanwhile computing power is becoming faster and less expensive over time
The biopharmaceutical industry has historically lacked the tools to understand biology’s complexity.
The opportunity
Recursion is leveraging technology to industrialize drug discovery
Recursion was founded to take advantage of the discontinuity between these fields and harness the power of accelerating technological innovations to improve the efficiency of drug discovery and development.
Harnessing value with a multi-pronged capital-efficient business strategy.
.png)
Pipeline Strategy
Build internal pipeline in indications with potential for accelerated path to approval. Learn more >
Precision Oncology
Rare Disease
.png)
Partnership Strategy
Partner in complex therapeutic areas requiring large financial commitment and competitive market dynamics.
Leverage partner knowledge and clinical development capabilities.
Learn more >
Neuroscience
Other large, intractable
areas of biology
.png)
Data Strategy
License subsets of data and key tools.
Direct generations of new data to maximize pipeline and partnership value-drivers. Learn more >
Licensing
Augment Recursion OS
Pipeline Strategy
Build internal pipeline in indications with potential for accelerated path to approval. Learn more >
Precision Oncology
Rare Disease
Partnership Strategy
Partner in complex therapeutic areas requiring large financial commitment and competitive market dynamics.
Leverage partner knowledge and clinical development capabilities. Learn more >
Neuroscience
Other large, intractable
areas of biology
Data Strategy
License subsets of data and key tools.
Direct generations of new data to maximize pipeline and partnership value-drivers. Learn more >
Licensing
Augment Recursion OS
Harnessing value with a multi-pronged capital-efficient business strategy.
Optimize for the
portfolio →
Optimize for the portfolio to accelerate programs at scale. We prioritize actions and decisions that promise to enhance our entire range of programs at scale.
Challenge assumptions and convention →
Challenge assumptions and conventions to uncover fundamental truth. We challenge and validate existing knowledge to foster rigorous thinking that bolsters innovation.
Build connected data →
Build connected data over collecting data points. We are creating a comprehensive, high-dimensional data network where all the data points are interconnected.
Explore the
uncharted →
Explore the uncharted over targeting the known. We’re not about drilling into the known; we’re about exploring the unknown, understudied areas of biology.
Industrialize
to scale →
Industrialize to scale exponentially through standardization and automation. We are instituting a system that automates key procedures and decisions, leading to substantial leaps in efficiency and output.
Virtuous cycles
of atoms & bits →
Create virtuous cycles of atoms and bits. Timely, iterative feedback accelerates our learning for both programs and platforms.
Failing faster and earlier...
Our goal is to leverage technology to reshape the typical drug discovery funnel by broadening the number of potential therapeutic starting points beyond hypothesized and human-biased targets, and then rapidly identifying failures earlier in the research cycle when they are relatively inexpensive.
Failing faster and earlier...
Our goal is to leverage technology to reshape the typical drug discovery funnel by broadening the number of potential therapeutic starting points beyond hypothesized and human-biased targets, and then rapidly identifying failures earlier in the research cycle when they are relatively inexpensive.
Failing faster and earlier...
to spend less and go faster
By leveraging technology at every step of the process, we can accelerate the development of high potential drug candidates once we have validated their potential.
Failing faster and earlier...
Our goal is to leverage technology to reshape the typical drug discovery funnel by broadening the number of potential therapeutic starting points beyond hypothesized and human-biased targets, and then rapidly identifying failures earlier in the research cycle when they are relatively inexpensive.
Failing faster and earlier...
Our goal is to leverage technology to reshape the typical drug discovery funnel by broadening the number of potential therapeutic starting points beyond hypothesized and human-biased targets, and then rapidly identifying failures earlier in the research cycle when they are relatively inexpensive.
Failing faster and earlier...
to spend less and go faster
By leveraging technology at every step of the process, we can accelerate the development of high potential drug candidates once we have validated their potential.
Drug discovery should be about helping patients, not developing patience.
Meaningfully accelerating the pace, broadening the scale, and decreasing the cost of bringing safe and effective new medicines to the patients who need them is one of the greatest challenges and largest opportunities for humanity.
